ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of "Hold" From Brokerages
ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of "Hold" From Brokerages
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) has earned a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $5.80.
据Marketbeat Ratings报道，ProQR治疗公司(纳斯达克代码：PRQR-GET Rating)已获得目前跟踪该股的9位分析师的共识评级为“持有”。五位股票研究分析师对该股的评级为持有建议，三位分析师对该公司发出了买入建议。在去年更新该股覆盖范围的经纪商中，12个月目标价的平均水平为5.80美元。
A number of research firms recently commented on PRQR. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price for the company in a research note on Friday, August 12th. Cantor Fitzgerald downgraded ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, August 15th. HC Wainwright decreased their target price on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Finally, Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, August 12th.
一些研究公司最近对PRQR发表了评论。在5月9日星期一的一份研究报告中，StockNews.com将ProQR治疗公司的评级从“卖出”上调为“持有”。Raymond James在8月12日(星期五)的一份研究报告中将ProQR治疗公司的评级从“市场表现”上调至“表现优于大盘”，并为该公司设定了2.00美元的目标价。Cantor Fitzgerald在8月15日星期一的一份研究报告中将ProQR治疗公司的评级从“增持”下调至“中性”。在5月9日星期一的一份研究报告中，HC Wainwright将他们对ProQR治疗的目标价格从4.00美元下调至2.00美元。最后，Chardan Capital在8月12日(星期五)的一份报告中将ProQR治疗公司的评级从“买入”下调至“中性”。
ProQR Therapeutics Stock Up 2.2 %
ProQR治疗公司股票上涨2.2%
NASDAQ:PRQR opened at $0.79 on Thursday. The company has a market capitalization of $56.31 million, a price-to-earnings ratio of -0.79 and a beta of 0.80. ProQR Therapeutics has a one year low of $0.53 and a one year high of $9.09. The stock has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 5.93.
纳斯达克：周四开盘报0.79美元。该公司市值为5,631万美元，市盈率为-0.79，贝塔系数为0.80。ProQR治疗公司的一年低点为0.53美元，一年高位为9.09美元。该股的50日简单移动均线切入位为0.81美元，200日简单移动均线切入位为0.84美元。该公司的负债权益比率为0.43，速动比率为5.93，流动比率为5.93。
Institutional Investors Weigh In On ProQR Therapeutics
机构投资者对ProQR治疗公司的看法
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. ProShare Advisors LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $80,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ProQR Therapeutics by 23.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 186,663 shares of the biopharmaceutical company's stock valued at $1,495,000 after buying an additional 35,261 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at $660,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of ProQR Therapeutics by 82.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,973 shares of the biopharmaceutical company's stock valued at $560,000 after buying an additional 31,614 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of ProQR Therapeutics by 14.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company's stock valued at $31,346,000 after buying an additional 481,325 shares in the last quarter. Institutional investors own 31.07% of the company's stock.
几家对冲基金和其他机构投资者最近增持或减持了PRQR的股份。ProShare Advisors LLC在第四季度购买了ProQR治疗公司的新股份，价值约8万美元。未来资产环球投资有限公司在第四季度增持了ProQR治疗公司的股票23.3%。未来资产全球投资有限公司(Mirae Asset Global Investments Co.Ltd.)目前持有这家生物制药公司186,663股股票，价值1,495,000美元，上个季度又购买了35,261股。Alps Advisors Inc.在第四季度购买了ProQR治疗公司新的股票头寸，价值66万美元。康纳·克拉克和伦恩投资管理有限公司在第四季度增持了82.4%的ProQR治疗公司的股票。康纳-克拉克-伦恩投资管理有限公司现在持有69,973股这家生物制药公司的股票，价值560,000美元，上个季度又购买了31,614股。最后，高盛股份有限公司在第四季度增持了ProQR治疗公司的股票14.0%。高盛股份有限公司现在持有这家生物制药公司3913,394股股票，价值31,346,000美元，上个季度又购买了481,325股。机构投资者持有该公司31.07%的股份。
ProQR Therapeutics Company Profile
ProQR治疗公司简介
(Get Rating)
(获取评级)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物制药公司，致力于发现和开发基于RNA的治疗遗传疾病的疗法。它主要开发正处于II/III期临床试验的sepofarsen，用于治疗Leber先天性黑发10病的照明试验；以及正在进行II/III期临床试验的ultevursen，用于治疗USH2A介导的视网膜色素变性和USHER综合征。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- 免费获取StockNews.com关于ProQR治疗(PRQR)的研究报告
- 阿里巴巴-SW和百度集团-SW最终能在退市恐惧中重整旗鼓吗？
- 世界摔跤娱乐公司准备被出售了吗？
- 3种可能在你的观察名单上获得一席之地的材料类股
- CrowdStrike股价回落，盈利超出预期
- 这些机构会在安巴雷拉入股抄底吗？
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProQR治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。